The Effect of Deprescribing

Waseem Jerjes,Daniele Ramsay,Harvey Stevenson,Karima Lalji
DOI: https://doi.org/10.3390/jcm13040958
IF: 3.9
2024-02-08
Journal of Clinical Medicine
Abstract:Background: Mental health (MH) polypharmacy, defined as prescribing multiple mental health medications for the same condition, presents significant challenges in clinical practice. With varying prevalence rates and an increasing trend, particularly in the UK, this deprescribing prospective quality improvement project aimed to address the complexities and risks associated with MH polypharmacy. Patients and Methods: A large primary care centre in London was selected for this project. Electronic records of 667 patients (non-coded in mental health lists) were analysed as a result of the absence of a Systematised Nomenclature of Medicine Clinical Terms (SNOMED CT) for mental health. Seventy-two non-coded patients exhibiting "same-class" as well as "adjunctive" and "augmentation" polypharmacy were identified. Their demographic and health data, including MH diagnoses, physical status, and lifestyle habits, were evaluated. This deprescribing prospective project included 68 patients and employed a model inspired by the Plan–Do–Study–Act (PDSA) cycle, focusing on reducing psychotropic, adjunctive, and augmentative medications while monitoring mental health control through face-to-face consultations using the Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder Assessment-7 (GAD-7) scores, alongside physical health parameters. Results: The project revealed a significant decrease in the average number of psychotropic and adjunct medications from initial consultations to the end of the 18-month period. Additionally, a marked reduction in reported side effects and drug interactions was observed. Improvements in mental health control, as evidenced by PHQ-9 and GAD-7 scores, were noted. Physical health parameters, including BMI, blood pressure, heart rate, HbA1c, and cholesterol levels, also showed significant improvements. Educational initiatives for patients and clinicians were successfully implemented, contributing to these positive outcomes. Discussion: The project faced challenges like balancing medication reduction with mental health stability, patient apprehension, and the absence of standardised protocols. However, the successful reduction in medication numbers and the improvement in health outcomes highlight the effectiveness of the model. This project underscores the necessity of a tailored approach to MH polypharmacy, emphasising continuous education, clinical titration, and adherence to guidelines. Future research is needed to develop clear guidelines for medication combination in mental health care and to understand the long-term effects of polypharmacy in mental health populations. Conclusions: This project demonstrates the potential for significant improvements in the management of MH polypharmacy. By carefully managing medication reductions and employing a comprehensive care approach, including patient education and clinician training, the project achieved improvements in both mental and physical health outcomes. These findings suggest a promising direction for future practices in MH polypharmacy management.
medicine, general & internal
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the complexity and risks of mental health polypharmacy (MH polypharmacy) in non - coded primary care patients. Specifically, the study aims to improve the physical and mental health of these patients by reducing drug prescriptions and to evaluate the impact of reducing drug use on patients' psychological control and physical parameters. The paper mentions that polypharmacy poses significant challenges in clinical practice, especially in the UK, where this trend is increasing. Therefore, through a model inspired by the Plan - Do - Study - Act (PDSA) cycle, this project systematically identifies and addresses potential problems related to anti - anxiety/depression drugs in the same treatment group in non - coded patients. ### Main problems: 1. **Complexity and risks of mental health polypharmacy**: Polypharmacy is defined as prescribing multiple mental health drugs for the same disease, and this practice poses significant challenges in clinical practice, including the risks of drug side effects and drug - drug interactions. 2. **Management of non - coded patients**: Due to the increase in the workload of primary care services and insufficient funding, many mental health patients not coded by the Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT) have not received routine monitoring, making them more likely to develop polypharmacy and comorbid conditions. 3. **Effect of reducing drug prescriptions**: The project evaluates the positive impact on patients' psychological control and physical health by reducing the use of mental health drugs. ### Research methods: - **Patient selection**: The study selected 667 non - coded patients from a large primary care center in London, among which 72 patients showed "same - class", "adjuvant" and "augmented" polypharmacy. - **Project model**: The Plan - Do - Study - Act (PDSA) cycle model was adopted, which is divided into five stages: "idea", "plan", "do", "study" and "act", and each stage has specific steps and goals. - **Data collection**: Changes in the number of mental health drugs, side effects, drug - drug interactions, and physical parameters (such as BMI, blood pressure, heart rate, HbA1c and cholesterol levels) of patients were recorded. ### Results: - **Reduction in the number of drugs**: From the initial consultation to the end of 18 months, the average number of mental health drugs per patient decreased significantly, from 2.4 to 1.3. - **Reduction in side effects and drug - drug interactions**: The number of side effects and drug - drug interactions reported by patients decreased from an initial 1.9 to 0.6. - **Improvement in physical and mental health**: Patients' mental health control (assessed by PHQ - 9 and GAD - 7 scores) and physical parameters (such as BMI, blood pressure, heart rate, HbA1c and cholesterol levels) all improved. ### Conclusion: This project shows that through careful management of drug reduction and the adoption of a comprehensive care approach, including patient education and doctor training, the management of mental health polypharmacy can be significantly improved. These findings provide a promising direction for the future management of mental health polypharmacy.